Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg |
ln Vitro |
In the human liver cancer HepG2 cell line, quinine hemisulfate (150 μM, 30 minutes) suppresses the growth and cytostatic effects of dengue virus [1]. In the human liver cancer HepG2 cell line, quinine hemisulfate (37.5-150 μM, 24 hours) substantially and dose-dependently decreased viral DENV RNA and protein levels [1].
|
---|---|
ln Vivo |
There is a certain inhibitory impact of quinine hemisulfate (oral gavage, 12 or 15 mg/kg, weekly, 16 weeks) on Swiss albino mice's development of skin cancer [2]. In the testicular tissue of male adult albino rats, quinine hemisulfate (oral gavage, 10 mg/kg, daily, 8 weeks) can produce a reduction in the antioxidant defense system (including SOD, CAT, and GSH enzyme activities) [3].
|
Cell Assay |
Cell proliferation assay [1]
Cell Types: Human hepatoma cell line (HepG2) Tested Concentrations: 150 μM Incubation Duration: 30 minutes Experimental Results: Compared with untreated, DENV virus replication was inhibited and the yield reached 19%. diminished DENV-positive cells from 23.28% to 12.05% in a dose-dependent manner. |
Animal Protocol |
Animal/Disease Models: Swiss albino mice 7-8 weeks (weight 24 grams) [2]
Doses: 12 mg/kg, 15 mg/kg Route of Administration: po (oral gavage); weekly; 16-week Experimental Results: 12 mg/kg dose Tumor size and weight were Dramatically diminished at 15 mg/kg, with little effect at higher doses of 15 mg/kg. |
References |
[1]. Shilu Malakar,et al. Drug repurposing of quinine as antiviral against dengue virus infection. Virus Res. 2018 Aug 15;255:171-178. doi: 10.1016/j.virusres.2018.07.018. Epub 2018 Jul 25.
[2]. Jhanwar, Deepika,et al. Chemoprevention of DMBA induced skin carcinogenesis in swiss albino mice by quinine sulfate.(2016): 2636-2640. [3]. Ebenezer O Farombi, et al. Quercetin protects against testicular toxicity induced by chronic administration of therapeutic dose of quinine sulfate in rats. J Basic Clin Physiol Pharmacol. 2012 Feb 27;23(1):39-44. |
Molecular Formula |
2[C20H24N2O2].H2O4S
|
---|---|
Molecular Weight |
746.912
|
CAS # |
804-63-7
|
Related CAS # |
Quinine hydrochloride dihydrate;6119-47-7;Quinine;130-95-0;Quinine sulfate hydrate;6119-70-6
|
SMILES |
O[C@H](C1=C2C=C(C=CC2=NC=C1)OC)[C@H]3N4CC[C@@]([H])(C3)[C@@H](C=C)C4.O=S(O)(O)=O
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.3388 mL | 6.6942 mL | 13.3885 mL | |
5 mM | 0.2678 mL | 1.3388 mL | 2.6777 mL | |
10 mM | 0.1339 mL | 0.6694 mL | 1.3388 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.